Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial.

ABSTRACT: This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting.

Design

Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days.

Setting

A retrospective analysis of data from the phase III CONFIRM study.

Participants

Adult patients with HRS-AKI admitted to the ICU.

Main outcomes and measures

In this substudy, we evaluated outcomes of the ICU stay and the need for organ support, including renal replacement therapy (RRT).

Results

Among 300 patients with HRS-AKI from the CONFIRM study, 45 were treated in the ICU (terlipressin, 31/199 [16%]; placebo, 14/101 [14%]). On ICU admission, baseline demographics were similar acro

SUBMITTER: Karvellas CJ 

PROVIDER: S-EPMC10060094 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature